CRISPR Therapeutics (CRSP) CEO RSU vesting and 9,798-share tax sale

Rhea-AI Filing Summary

CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported compensation-related share activity. On March 10, 2026, 19,250 restricted stock units were exercised into 19,250 Common Shares at $0.00 per share, reflecting vesting of part of a prior equity award.

On March 11, 2026, 9,798 Common Shares were sold at $52.80 per share. A footnote explains this amount was required to be sold to cover tax withholding tied to the RSU vesting under the company’s RSU Settlement Policy, and therefore did not represent a discretionary trade. After these transactions, Kulkarni directly held 235,558 Common Shares.

Insider Trade Summary

Net Seller: 9,798 shares ($517,334)

Net Sell 3 txns

Insider Kulkarni Samarth

Role Chief Executive Officer

Sold 9,798 shs ($517K)

Type	Security	Shares	Price	Value
Sale	Common Shares	9,798	$52.80	$517K
Exercise	Restricted Stock Units	19,250	$0.00	--
Exercise	Common Shares	19,250	$0.00	--

Holdings After Transaction: Common Shares — 235,558 shares (Direct); Restricted Stock Units — 19,250 shares (Direct)

Footnotes (1)

1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. This restricted stock unit award was granted on March 10, 2023 with respect to 77,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kulkarni Samarth

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MA 02127

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/10/2026		M(1)		19,250	A	(2)	245,356	D
Common Shares	03/11/2026		S		9,798(3)	D	$52.8	235,558	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/10/2026		M(1)			19,250	(4)	(4)	Common Shares	19,250	(2)	19,250	D

Explanation of Responses:

1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

3. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

4. This restricted stock unit award was granted on March 10, 2023 with respect to 77,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.

	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CRISPR Therapeutics (CRSP) CEO Samarth Kulkarni report in this Form 4?

CRISPR Therapeutics CEO Samarth Kulkarni reported RSU vesting and a related share sale. 19,250 restricted stock units converted into Common Shares, and 9,798 shares were sold to cover tax withholding obligations under the company’s RSU Settlement Policy, leaving 235,558 shares held directly.

How many CRISPR Therapeutics shares did the CEO sell and at what price?

Samarth Kulkarni sold 9,798 CRISPR Therapeutics Common Shares at a price of $52.80 per share. A filing footnote states the sale was required to cover tax withholding from RSU vesting, under the company’s RSU Settlement Policy, rather than being a discretionary market trade.

Was the CRSP CEO share sale a discretionary transaction or tax-related?

The share sale was tax-related rather than discretionary. A footnote explains the 9,798 shares were sold to satisfy tax withholding obligations triggered by restricted stock unit vesting, pursuant to CRISPR Therapeutics’ RSU Settlement Policy, meaning the transaction did not reflect an independent trading decision by the CEO.

How many CRISPR Therapeutics shares does the CEO hold after these transactions?

After the reported transactions, Samarth Kulkarni directly held 235,558 CRISPR Therapeutics Common Shares. This figure reflects the conversion of 19,250 restricted stock units into shares and the sale of 9,798 shares for tax withholding, as detailed in the Form 4 filing’s transaction table.

What are the terms of the CRSP restricted stock unit award mentioned in the filing?

The restricted stock unit award was granted on March 10, 2023 for 77,000 Common Shares. One quarter vests on March 10 of each year from 2024 through 2027. Each unit represents a contingent right to receive one CRISPR Therapeutics Common Share upon vesting.

What does each CRISPR Therapeutics restricted stock unit represent for the CEO?

Each restricted stock unit represents a contingent right to receive one CRISPR Therapeutics Common Share. As units vest according to the award schedule, they convert into Common Shares, which can then be subject to tax withholding transactions such as the mandated sale disclosed in this Form 4.